-
Electronic (PDF)
-
Site License
-
Enterprisewide
ProMetic Life Sciences Inc. - Product Pipeline Review - H2 2011
Global Markets Direct, November 2011, Pages: 78
ProMetic Life Sciences Inc. – Product Pipeline Review – H2 2011
Summary
Global Market Direct’s pharmaceuticals report, “ProMetic Life Sciences Inc. - Product Pipeline Review - H2 2011” provides data on the ProMetic Life Sciences Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, ProMetic Life Sciences Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from ProMetic Life Sciences Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- ProMetic Life Sciences Inc. - Brief ProMetic Life Sciences Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of ProMetic Life Sciences Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of ProMetic Life Sciences Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the ProMetic Life Sciences Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate ProMetic Life Sciences Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of ProMetic Life Sciences Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the ProMetic Life Sciences Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with ProMetic Life Sciences Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of ProMetic Life Sciences Inc. and identify potential opportunities in those areas.
Keywords
Current R&D Portfolio of ProMetic Life Sciences Inc.; ProMetic Life Sciences Inc. - Key Therapeutics; ProMetic Life Sciences Inc. - Pipeline Overview and Promising Molecules; ProMetic Life Sciences Inc. - News; ProMetic Life Sciences Inc. - Latest Updates; ProMetic Life Sciences Inc. - Pipeline; ProMetic Life Sciences Inc. - Discontinued/Dormant Projects
List of Tables
List of Figures
ProMetic Life Sciences Inc. Snapshot
ProMetic Life Sciences Inc. Overview
Key Information
Key Facts
ProMetic Life Sciences Inc. – Research and Development Overview
Key Therapeutic Areas
ProMetic Life Sciences Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
ProMetic Life Sciences Inc. – Pipeline Products Glance
ProMetic Life Sciences Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
ProMetic Life Sciences Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
ProMetic Life Sciences Inc. – Drug Profiles
PBI-0110
Product Description
Mechanism of Action
R&D Progress
PBI-1393
Product Description
Mechanism of Action
R&D Progress
PBI-1402
Product Description
Mechanism of Action
R&D Progress
PBI-1522
Product Description
Mechanism of Action
R&D Progress
PBI-1668
Product Description
Mechanism of Action
R&D Progress
PBI-1737
Product Description
Mechanism of Action
R&D Progress
PBI-1737 + Cyclophosphamide
Product Description
Mechanism of Action
R&D Progress
PBI-4050
Product Description
Mechanism of Action
R&D Progress
ProMetic Life Sciences Inc. – Pipeline Analysis
ProMetic Life Sciences Inc. – Pipeline Products by Therapeutic Class
ProMetic Life Sciences Inc. - Pipeline Products By Target
ProMetic Life Sciences Inc. – Pipeline Products by Route of Administration
ProMetic Life Sciences Inc. – Pipeline Products by Molecule Type
ProMetic Life Sciences Inc. – Recent Pipeline Updates
ProMetic Life Sciences Inc. - Dormant Projects
ProMetic Life Sciences Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Jan 30, 2007: Prometic Completes Preclinical Toxicology Studies Of PBI-1393 In Support Of Offshore Clinical Trial For Advanced Cervical Cancer
Apr 17, 2008: Prometic Presents Preclinical Data For Prostate And Pancreatic Cancer At The AACR Meeting
Dec 10, 2007: Phase II Trial Of ProMetic’s PBI-1402 Shows Significantly Increased Red Blood Cell Count And Hemoglobin In Chemotherapy-Induced Anemia Patients
Financial Deals Landscape
ProMetic Life Sciences Inc., Deals Summary
ProMetic Life Sciences Inc., Pharmaceuticals & Healthcare, Deal Details
Partnerships
ProMetic Enters Into Strategic Agreement With Allist Pharmaceuticals For PBI-1402 And PBI-4419
Novozymes Enters Into Co-Marketing Agreement With ProMetic Life Sciences
ProMetic Life Sciences Enters Into Co-Development Agreement With Abraxis BioScience
HemCon Medical Technologies Enters Into Co-Development Agreement With ProMetic Biosciences
ProMetic And Laboratorios Dermatologicos Enter Into Co-Development Agreement
Novartis Enters Into Co-Development Agreement With ProMetic Biosciences
Sartorius Enters Into Co-Development Agreement With ProMetic BioSciences
ProMetic Life Sciences Signs Co-Development Agreement With Octapharma
ProMetic Biosciences Enters Into Co-Development Agreement With Serono
Licensing Agreements
Kedrion Enters Into Licensing Agreement With ProMetic Life Science
ProMetic Life Sciences Enters Into Licensing Agreement With Instituto de Tecnologia do Parana
ProMetic Life Sciences Expands Licensing Agreement With Wuhan Institute
ProMetic Enters Into An Agreement With Celgene
Abraxis Enters Into License Agreement With ProMetic Life Sciences
ProMetic Life Sciences Enters Into Licensing Agreement With Wuhan Institute of Biological Products
ProMetic Life Sciences Enters Into Licensing Agreement With Tecpar
Nabi Biopharmaceuticals Enters Into Agreement With ProMetic Life Sciences
ProMetic Enters Into Technology Licensing Agreement With BioMena
Equity Offering
ProMetic Life Sciences Completes Private Placement Of $3 Million
ProMetic Completes Private Placement Of $7 Million
ProMetic Life Sciences Completes Private Placement Of $5 Million
ProMetic Completes Private Placement Of $1 Million
ProMetic Completes Private Placement Of $6 Million
ProMetic Life Sciences Completes Private Placement Of $7.9 Million
ProMetic Life Sciences Completes Private Placement Of $6.9 Million
ProMetic Completes Private Placement Of $11 Million
ProMetic Completes Public Offering Of $15 Million
Debt Offering
ProMetic Completes Private Placement Of Senior Notes For $8.9 Million
Acquisition
ProMetic Life Sciences Acquires Additional 51% Stake In Pathogen Removal And Diagnostic Technologies From American Red Cross
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
ProMetic Life Sciences Inc. – Pipeline by Therapy Area and Indication, H2 2011
ProMetic Life Sciences Inc. – Pipeline by Stage of Development, H2 2011
ProMetic Life Sciences Inc. – Monotherapy Products in Pipeline, H2 2011
ProMetic Life Sciences Inc. – Combination Treatment Modalities in Pipeline, H2 2011
ProMetic Life Sciences Inc. - Phase II, H2 2011
ProMetic Life Sciences Inc. - Pipeline By Therapeutic Class, H2 2011
ProMetic Life Sciences Inc. - Pipeline By Target, H2 2011
ProMetic Life Sciences Inc. – Pipeline By Route of Administration, H2 2011
ProMetic Life Sciences Inc. – Pipeline By Molecule Type, H2 2011
ProMetic Life Sciences Inc. – Recent Pipeline Updates, H2 2011
ProMetic Life Sciences Inc. - Dormant Developmental Projects, 2010
ProMetic Life Sciences Inc., Other Locations
ProMetic Life Sciences Inc., Subsidiaries
ProMetic Life Sciences Inc., Deals Summary
ProMetic Enters Into Strategic Agreement With Allist Pharmaceuticals For PBI-1402 And PBI-4419
Novozymes Enters Into Co-Marketing Agreement With ProMetic Life Sciences
ProMetic Life Sciences Enters Into Co-Development Agreement With Abraxis BioScience
HemCon Medical Technologies Enters Into Co-Development Agreement With ProMetic Biosciences
ProMetic And Laboratorios Dermatologicos Enter Into Co-Development Agreement
Novartis Enters Into Co-Development Agreement With ProMetic Biosciences
Sartorius Enters Into Co-Development Agreement With ProMetic BioSciences
ProMetic Life Sciences Signs Co-Development Agreement With Octapharma
ProMetic Biosciences Enters Into Co-Development Agreement With Serono
Kedrion Enters Into Licensing Agreement With ProMetic Life Science
ProMetic Life Sciences Enters Into Licensing Agreement With Instituto de Tecnologia do Parana
ProMetic Life Sciences Expands Licensing Agreement With Wuhan Institute
ProMetic Enters Into An Agreement With Celgene
Abraxis Enters Into License Agreement With ProMetic Life Sciences
ProMetic Life Sciences Enters Into Licensing Agreement With Wuhan Institute of Biological Products
ProMetic Life Sciences Enters Into Licensing Agreement With Tecpar
Nabi Biopharmaceuticals Enters Into Agreement With ProMetic Life Sciences
ProMetic Enters Into Technology Licensing Agreement With BioMena
ProMetic Life Sciences Completes Private Placement Of $3 Million
ProMetic Completes Private Placement Of $7 Million
ProMetic Life Sciences Completes Private Placement Of $5 Million
ProMetic Completes Private Placement Of $1 Million
ProMetic Completes Private Placement Of $6 Million
ProMetic Life Sciences Completes Private Placement Of $7.9 Million
ProMetic Life Sciences Completes Private Placement Of $6.9 Million
ProMetic Completes Private Placement Of $11 Million
ProMetic Completes Public Offering Of $15 Million
ProMetic Completes Private Placement Of Senior Notes For $8.9 Million
ProMetic Life Sciences Acquires Additional 51% Stake In Pathogen Removal And Diagnostic Technologies From American Red Cross
List of Figures
ProMetic Life Sciences Inc. – Pipeline by Therapy Area and Indication, H2 2011
ProMetic Life Sciences Inc. – Pipeline by Stage of Development, H2 2011
ProMetic Life Sciences Inc. – Monotherapy Products in Pipeline, H2 2011
ProMetic Life Sciences Inc. – Combination Treatment Modalities in Pipeline, H2 2011
ProMetic Life Sciences Inc. – Pipeline By Therapeutic Class, H2 2011
ProMetic Life Sciences Inc. - Pipeline By Target, H2 2011
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
